Ardelyx, Inc. Earnings Recaps
Q2 2026
Aug 10, 2026
Ardelyx shares fell 18.5% after the company cut guidance in response to growing payer hurdles that slowed new patient starts for IBSRELA, signaling investor concerns over demand deceleration despite revenue growth.
Key takeaways
- Combined revenue from IBSRELA and XPHOZAH reached $118 million, up 31% year-over-year and the highest quarterly total in company history.
- New patient starts for IBSRELA were materially impacted by increased payer restrictions, dampening growth momentum.
- Refill rates and total prescriptions hit record highs, supported by the IBSRELA Pharmacy Network and expanded sales force initiatives.
- The company highlighted ongoing efforts to mitigate payer barriers, including doubling the field reimbursement team and ramping up direct-to-consumer marketing.
- Management reaffirmed long-term revenue potential but will no longer pursue further legal action regarding CMS reimbursement, removing a potential lever for future pricing flexibility.
Q3 2025
Oct 31, 2025
Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.
Key takeaways
- Total product revenue reached $105.5 million, a 15% increase year-over-year.
- IBSRELA generated $78.2 million, a record high, with an upward revision of revenue guidance to $270-$275 million for the year.
- XPHOZAH contributed $27.4 million in revenue, reflecting a 9% increase from the previous quarter.
- Introduction of ARDX-10531, a next-generation NHE3 inhibitor, marks a significant step in expanding the company’s pipeline.
- Strong leadership addition with Sue Hohenleitner as CFO, enhancing financial and strategic insights.